PLEKHA2

Summary

PLEKHA2 (pleckstrin homology domain containing A2, HGNC:14336) is a protein-coding gene on chromosome 8p11.22, encoding Pleckstrin homology domain-containing family A member 2 (Q9HB19). Binds specifically to phosphatidylinositol 3,4-diphosphate (PtdIns3,4P2), but not to other phosphoinositides.

Enables fibronectin binding activity; laminin binding activity; and phosphatidylinositol-3,4-bisphosphate binding activity. Involved in positive regulation of cell-matrix adhesion. Located in cytoplasm and membrane. Part of protein-containing complex.

Source: NCBI Gene 59339 — RefSeq curated summary.

At a glance

• GWAS associations: 2
• Clinical variants (ClinVar): 54 total
• MANE Select transcript: NM_021623

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:14336
Approved symbol	PLEKHA2
Name	pleckstrin homology domain containing A2
Location	8p11.22
Locus type	gene with protein product
Status	Approved
Aliases	TAPP2
Ensembl gene	ENSG00000169499
Ensembl biotype	protein_coding
OMIM	607773
Entrez	59339

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 6 protein_coding, 3 protein_coding_CDS_not_defined, 1 retained_intron

ENST00000518070, ENST00000518939, ENST00000519640, ENST00000521123, ENST00000521382, ENST00000521746, ENST00000616834, ENST00000616927, ENST00000617275, ENST00000903010

RefSeq mRNA: 2 — MANE Select: NM_021623 NM_001410925, NM_021623

CCDS: CCDS75732, CCDS94287

Canonical transcript exons

ENST00000617275 — 12 exons

Exon	Start	End
ENSE00003526734	38950850	38950990
ENSE00003542564	38952636	38952704
ENSE00003579400	38952166	38952312
ENSE00003592062	38917907	38918070
ENSE00003619269	38943789	38943837
ENSE00003629963	38935994	38936050
ENSE00003713647	38969421	38973912
ENSE00003716153	38953297	38953367
ENSE00003724704	38957323	38957386
ENSE00003732247	38901346	38901445
ENSE00003735647	38968592	38968669
ENSE00003788406	38946124	38946221

Expression profiles

Bgee: expression breadth ubiquitous, 265 present calls, max score 97.02.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 17.7278 / max 255.1682, expressed in 1716 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
88545	7.9536	1486
88544	2.8535	1058
88540	2.5862	1310
88542	1.2954	622
88541	1.2739	746
88543	1.1515	531
88546	0.3540	173
88539	0.2599	114

Top tissues by expression

288 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
synovial joint	UBERON:0002217	97.02	gold quality
visceral pleura	UBERON:0002401	96.89	gold quality
parietal pleura	UBERON:0002400	96.74	gold quality
amniotic fluid	UBERON:0000173	96.12	gold quality
middle temporal gyrus	UBERON:0002771	95.92	gold quality
epithelium of nasopharynx	UBERON:0001951	95.68	gold quality
palpebral conjunctiva	UBERON:0001812	95.61	gold quality
dorsal root ganglion	UBERON:0000044	95.43	gold quality
germinal epithelium of ovary	UBERON:0001304	95.22	gold quality
superficial temporal artery	UBERON:0001614	95.08	gold quality
trigeminal ganglion	UBERON:0001675	95.07	gold quality
seminal vesicle	UBERON:0000998	94.98	gold quality
trabecular bone tissue	UBERON:0002483	94.88	gold quality
lymph node	UBERON:0000029	94.76	gold quality
pleura	UBERON:0000977	94.63	gold quality
vena cava	UBERON:0004087	94.45	gold quality
endothelial cell	CL:0000115	94.35	gold quality
tendon of biceps brachii	UBERON:0008188	94.34	gold quality
Brodmann (1909) area 23	UBERON:0013554	94.26	gold quality
heart right ventricle	UBERON:0002080	94.13	gold quality
saphenous vein	UBERON:0007318	93.87	gold quality
adult organism	UBERON:0007023	93.72	gold quality
urethra	UBERON:0000057	93.41	gold quality
esophagus squamous epithelium	UBERON:0006920	93.31	gold quality
renal medulla	UBERON:0000362	93.15	gold quality
pericardium	UBERON:0002407	92.92	gold quality
pigmented layer of retina	UBERON:0001782	92.84	gold quality
colonic epithelium	UBERON:0000397	92.70	gold quality
monocyte	CL:0000576	92.68	gold quality
caput epididymis	UBERON:0004358	92.68	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-CURD-119	yes	22.44
E-MTAB-9067	yes	17.51
E-ANND-3	yes	10.79

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR1I2

miRNA regulators (miRDB)

122 targeting PLEKHA2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-371B-5P	99.99	75.34	4759
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-373-5P	99.98	75.36	4753
HSA-MIR-616-5P	99.98	75.58	4775
HSA-MIR-27A-3P	99.98	72.13	2955
HSA-MIR-27B-3P	99.98	72.13	2955
HSA-MIR-9985	99.98	72.11	2939
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-2110	99.96	66.68	1930
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-548AJ-3P	99.96	73.38	5345
HSA-MIR-548X-3P	99.96	73.38	5345
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-1236-3P	99.94	68.04	1695
HSA-MIR-548J-3P	99.94	72.61	4881

Literature-anchored findings (GeneRIF, showing 2)

• These findings identify TAPP2 as a novel link between PI3K signaling and the cytoskeleton with potential relevance for leukemia progression. (PMID:19786618)
• This study identified TAPP2 as a novel regulator of malignant B cell migration. (PMID:23460911)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	plekha2	ENSDARG00000078221
mus_musculus	Plekha2	ENSMUSG00000031557
rattus_norvegicus	Plekha2	ENSRNOG00000066109

Paralogs (1): PLEKHA1 (ENSG00000107679)

Protein

Protein identifiers

Pleckstrin homology domain-containing family A member 2 — Q9HB19 (reviewed: Q9HB19)

Alternative names: Tandem PH domain-containing protein 2

All UniProt accessions (5): A0A087WZ32, A0A087X038, E5RGP3, E5RHB5, Q9HB19

UniProt curated annotations — full annotation on UniProt →

Function. Binds specifically to phosphatidylinositol 3,4-diphosphate (PtdIns3,4P2), but not to other phosphoinositides. May recruit other proteins to the plasma membrane.

Subunit / interactions. Binds MPDZ and PTPN13.

Subcellular location. Cytoplasm. Cell membrane. Nucleus.

Tissue specificity. Highly expressed in heart, kidney, spleen and peripheral blood leukocytes. Detected at lower levels in brain, skeletal muscle, colon, thymus, liver, small intestine, placenta and lung.

RefSeq proteins (2): NP_001397854, NP_067636* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001849	PH_domain	Domain
IPR011993	PH-like_dom_sf	Homologous_superfamily
IPR051707	PI-Interact_SigTrans_Reg	Family

Pfam: PF00169

UniProt features (13 total): modified residue 3, domain 2, region of interest 2, compositionally biased region 2, chain 1, cross-link 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9HB19-F1	72.12	0.44

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 141, 184, 314, 349

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-1660499	Synthesis of PIPs at the plasma membrane

MSigDB gene sets: 206 (showing top): GRAESSMANN_APOPTOSIS_BY_SERUM_DEPRIVATION_DN, GOBP_POSITIVE_REGULATION_OF_CELL_ADHESION, GOBP_POSITIVE_REGULATION_OF_CELL_MATRIX_ADHESION, FOSTER_TOLERANT_MACROPHAGE_UP, PID_PI3KCI_PATHWAY, GOBP_REGULATION_OF_CELL_SUBSTRATE_ADHESION, GOBP_REGULATION_OF_CELL_MATRIX_ADHESION, GOBP_CELL_SUBSTRATE_ADHESION, MARTORIATI_MDM4_TARGETS_FETAL_LIVER_UP, GOBP_CELL_MATRIX_ADHESION, GOBP_POSITIVE_REGULATION_OF_CELL_SUBSTRATE_ADHESION, SENESE_HDAC3_TARGETS_DN, PASQUALUCCI_LYMPHOMA_BY_GC_STAGE_DN, GOMF_EXTRACELLULAR_MATRIX_BINDING, THUM_SYSTOLIC_HEART_FAILURE_DN

GO Biological Process (1): positive regulation of cell-matrix adhesion (GO:0001954)

GO Molecular Function (7): fibronectin binding (GO:0001968), phospholipid binding (GO:0005543), PDZ domain binding (GO:0030165), laminin binding (GO:0043236), phosphatidylinositol-3,4-bisphosphate binding (GO:0043325), protein binding (GO:0005515), lipid binding (GO:0008289)

GO Cellular Component (5): nucleus (GO:0005634), cytoplasm (GO:0005737), plasma membrane (GO:0005886), membrane (GO:0016020), protein-containing complex (GO:0032991)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
PI Metabolism	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein binding	2
binding	2
cellular anatomical structure	2
regulation of cell-matrix adhesion	1
cell-matrix adhesion	1
positive regulation of cell-substrate adhesion	1
lipid binding	1
protein domain specific binding	1
extracellular matrix binding	1
phosphatidylinositol bisphosphate binding	1
intracellular membrane-bounded organelle	1
intracellular anatomical structure	1
membrane	1
cell periphery	1
cellular_component	1

Protein interactions and networks

STRING

1372 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
PLEKHA2	PLEK2	Q9NYT0	717
PLEKHA2	TM2D2	Q9BX73	620
PLEKHA2	HTRA4	P83105	544
PLEKHA2	UTRN	P46939	531
PLEKHA2	ADAM32	Q8TC27	516
PLEKHA2	PLEKHA3	Q9HB20	509
PLEKHA2	TACC1	O75410	478
PLEKHA2	PLEKHA8	Q96JA3	475
PLEKHA2	FAM110A	Q9BQ89	470
PLEKHA2	ZMAT4	Q9H898	439
PLEKHA2	DCUN1D2	Q6PH85	439
PLEKHA2	TUBGCP5	Q96RT8	414
PLEKHA2	TACC2	O95359	402
PLEKHA2	STXBP4	Q6ZWJ1	400
PLEKHA2	PLEKHA4	Q9H4M7	394

IntAct

201 interactions, top by confidence:

A	B	Type	Score
PLEKHA2	MPDZ	psi-mi:“MI:0407”(direct interaction)	0.700
PLEKHA2	MPDZ	psi-mi:“MI:0915”(physical association)	0.700
LNX1	PLEKHA2	psi-mi:“MI:0915”(physical association)	0.680
DLG3	PLEKHA2	psi-mi:“MI:0915”(physical association)	0.680
DLG2	PLEKHA2	psi-mi:“MI:0915”(physical association)	0.680
PLEKHA2	SNTG1	psi-mi:“MI:0915”(physical association)	0.680
PLEKHA2	SNTG1	psi-mi:“MI:0407”(direct interaction)	0.680
PLEKHA2	LNX1	psi-mi:“MI:0407”(direct interaction)	0.680
PLEKHA2	DLG3	psi-mi:“MI:0407”(direct interaction)	0.680
PLEKHA2	DLG2	psi-mi:“MI:0407”(direct interaction)	0.680
YWHAH	PLEKHG3	psi-mi:“MI:0914”(association)	0.610
PLEKHA2	PTPN13	psi-mi:“MI:0407”(direct interaction)	0.610
PTPN13	PLEKHA2	psi-mi:“MI:0915”(physical association)	0.610
MPDZ	SMCHD1	psi-mi:“MI:0914”(association)	0.590
PLEKHA2	SNTB1	psi-mi:“MI:0407”(direct interaction)	0.590
PLEKHA2	SNTA1	psi-mi:“MI:0407”(direct interaction)	0.590
PLEKHA2	EGLN3	psi-mi:“MI:0915”(physical association)	0.560
PLEKHA2	TEPSIN	psi-mi:“MI:0915”(physical association)	0.560
M1AP	PLEKHA2	psi-mi:“MI:0915”(physical association)	0.560
KANK2	PLEKHA2	psi-mi:“MI:0915”(physical association)	0.560
GOLGA2	PLEKHA2	psi-mi:“MI:0915”(physical association)	0.560
PLEKHA2	COG6	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (117): PLEKHA2 (Proximity Label-MS), PLEKHA2 (Affinity Capture-RNA), PLEKHA2 (Affinity Capture-RNA), PLEKHA2 (Affinity Capture-MS), PLEKHA2 (Proximity Label-MS), PTPN13 (Reconstituted Complex), YWHAH (Affinity Capture-MS), KRAS (Affinity Capture-MS), YWHAQ (Affinity Capture-MS), GRB2 (Affinity Capture-MS), RAC2 (Affinity Capture-MS), RALA (Affinity Capture-MS), PTPN6 (Affinity Capture-MS), UTRN (Affinity Capture-MS), TUBGCP2 (Affinity Capture-MS)

ESM2 similar proteins: A1L2W9, B2RQE8, B5XG43, G9CGD6, O08969, O88387, P59113, Q0V987, Q0VC85, Q1KKW7, Q1KKZ1, Q32LP0, Q3UUV5, Q3ZBA3, Q4V7G1, Q503L1, Q53GA4, Q5FVW6, Q5PQT7, Q5R8M5, Q5U597, Q5XGP7, Q5ZL23, Q6P0G8, Q6PG29, Q7Z628, Q7Z6J4, Q80VL0, Q80YS6, Q86UX7, Q86WV1, Q8AW35, Q8BY35, Q8IZC4, Q8K1B8, Q8N556, Q8VH46, Q91ZM9, Q91ZT5, Q925E0

Diamond homologs: B6RSP1, D3ZL52, G9CGD6, O08967, O43739, P54644, P60669, P97434, P97696, Q3UIL6, Q5DU31, Q6IQ23, Q6WCQ1, Q6ZNL6, Q7TQG1, Q80UZ0, Q80VL0, Q80YA9, Q86IV4, Q8BH49, Q8C4V1, Q8N264, Q8N4B1, Q8VC98, Q8WWN9, Q8WXI2, Q99KW3, Q9ERE6, Q9ERS5, Q9H4M7, Q9HAU0, Q9HB19, Q9Y2H5, Q9Z1T4, A1CYS1, A2QNQ5, A6QLU3, P09851, P20936, P42331

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 109 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Activation of BAD and translocation to mitochondria	6	63.4×	2e-08
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	6	56.0×	3e-08
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	6	56.0×	3e-08
Activation of BH3-only proteins	6	41.4×	2e-07
Dopamine Neurotransmitter Release Cycle	5	34.5×	6e-06
Assembly and cell surface presentation of NMDA receptors	9	31.7×	1e-09
RHO GTPases activate PKNs	7	30.8×	9e-08
Neurexins and neuroligins	11	30.1×	2e-11

GO biological processes:

GO term	Partners	Fold	FDR
establishment or maintenance of epithelial cell apical/basal polarity	10	56.4×	6e-13
protein localization to synapse	6	44.6×	5e-07
receptor clustering	6	36.4×	1e-06
regulation of postsynaptic membrane neurotransmitter receptor levels	7	33.7×	3e-07
protein targeting	8	28.4×	1e-07
protein-containing complex assembly	9	9.9×	2e-05
cell-cell adhesion	10	9.9×	7e-06
intracellular protein localization	9	9.2×	4e-05

Disease & clinical

Clinical variants and AI predictions

ClinVar

54 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	39
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2121 predictions. Top by Δscore:

Variant	Effect	Δscore
8:38901441:GGGGG:G	donor_gain	1.0000
8:38901442:GGGG:G	donor_gain	1.0000
8:38901442:GGGGG:G	donor_gain	1.0000
8:38901443:GGG:G	donor_gain	1.0000
8:38901443:GGGG:G	donor_gain	1.0000
8:38901444:GG:G	donor_gain	1.0000
8:38901444:GGG:G	donor_gain	1.0000
8:38901445:GG:G	donor_gain	1.0000
8:38946110:T:TA	acceptor_gain	1.0000
8:38946112:T:TA	acceptor_gain	1.0000
8:38946113:G:A	acceptor_gain	1.0000
8:38946121:TAGTT:T	acceptor_loss	1.0000
8:38946122:A:AG	acceptor_gain	1.0000
8:38946122:A:AT	acceptor_loss	1.0000
8:38946123:G:GT	acceptor_gain	1.0000
8:38946123:GT:G	acceptor_gain	1.0000
8:38946123:GTT:G	acceptor_gain	1.0000
8:38946123:GTTA:G	acceptor_gain	1.0000
8:38946123:GTTAT:G	acceptor_gain	1.0000
8:38946217:TCACC:T	donor_gain	1.0000
8:38946220:CC:C	donor_gain	1.0000
8:38946222:G:GG	donor_gain	1.0000
8:38946227:T:G	donor_gain	1.0000
8:38950838:C:A	acceptor_gain	1.0000
8:38950986:GCCAG:G	donor_gain	1.0000
8:38950987:CCAGG:C	donor_loss	1.0000
8:38950988:CAGGT:C	donor_loss	1.0000
8:38950989:AGGT:A	donor_loss	1.0000
8:38950990:GGTGA:G	donor_loss	1.0000
8:38950991:GT:G	donor_loss	1.0000

AlphaMissense

2793 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
8:38917955:G:C	R9P	1.000
8:38917963:G:T	G12W	1.000
8:38917964:G:A	G12E	1.000
8:38917966:T:C	F13L	1.000
8:38917968:T:A	F13L	1.000
8:38917968:T:G	F13L	1.000
8:38946186:T:A	W104R	1.000
8:38946186:T:C	W104R	1.000
8:38946188:G:C	W104C	1.000
8:38946188:G:T	W104C	1.000
8:38952298:A:G	K207E	1.000
8:38952300:G:C	K207N	1.000
8:38952300:G:T	K207N	1.000
8:38952645:T:A	W215R	1.000
8:38952645:T:C	W215R	1.000
8:38952647:G:C	W215C	1.000
8:38952647:G:T	W215C	1.000
8:38952654:C:A	R218S	1.000
8:38952661:T:C	F220S	1.000
8:38957346:T:C	L266P	1.000
8:38957349:T:C	F267S	1.000
8:38968619:T:A	W289R	1.000
8:38968619:T:C	W289R	1.000
8:38917934:C:A	P2H	0.999
8:38917963:G:A	G12R	0.999
8:38917963:G:C	G12R	0.999
8:38917964:G:T	G12V	0.999
8:38917970:T:C	L14P	0.999
8:38918014:T:G	Y29D	0.999
8:38918018:T:C	F30S	0.999

dbSNP variants (sampled 300 via entrez): RS1000045674 (8:38918771 A>G), RS1000077674 (8:38921211 T>C), RS1000165257 (8:38928269 G>A), RS1000248745 (8:38960500 G>A,T), RS1000253307 (8:38949031 C>T), RS1000364789 (8:38927976 A>C), RS1000370870 (8:38927334 AAAAAT>A), RS1000460634 (8:38973390 G>A), RS1000493382 (8:38967321 G>A,C), RS1000507103 (8:38961385 A>C), RS1000507246 (8:38945253 G>A), RS1000526216 (8:38932755 C>T), RS1000558718 (8:38901995 C>T), RS1000633156 (8:38908710 A>G), RS1000639988 (8:38938498 TG>T)

Disease associations

OMIM: gene MIM:607773 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST008444_8	High density lipoprotein cholesterol levels	8.000000e-06
GCST90002394_275	Monocyte percentage of white cells	4.000000e-11

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0007989	monocyte percentage of leukocytes

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

63 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, increases expression	5
Benzo(a)pyrene	decreases expression, decreases methylation, increases expression, affects methylation	4
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	3
Cyclosporine	decreases expression	3
Particulate Matter	increases abundance, affects cotreatment, decreases expression	3
mercuric bromide	affects cotreatment, increases expression	2
entinostat	increases expression, affects cotreatment	2
(+)-JQ1 compound	decreases expression	2
Air Pollutants	increases abundance, decreases expression	2
Ethanol	decreases expression, increases abundance, affects cotreatment, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
aristolochic acid I	decreases expression	1
FR900359	decreases phosphorylation	1
TAK-243	increases sumoylation	1
trichostatin A	increases expression	1
sodium arsenite	decreases expression	1
potassium chromate(VI)	decreases expression	1
cupric chloride	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression, affects cotreatment, decreases expression	1
2-palmitoylglycerol	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
torcetrapib	increases expression	1
belinostat	decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, increases expression	1
licochalcone B	decreases expression	1
bisphenol S	increases expression	1
Decitabine	affects expression	1
Sunitinib	increases expression	1
Vorinostat	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.